Skip to main content
 

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

It is estimated that more than 5 million people in the United State are diagnosed with NVAF and an additional 3 million have AFib and don’t know it (Colilla S et al. Am J Cardiol.2014;pii: S0002-9149(13)-1288). The BMS/Pfizer Alliance and AHA are working together to identify undiagnosed patients and provide digital tools to manage the condition. The first phase of this study involves the development of a screening tool using a combination of pharmacy, hospital, claims and EHR data in order to identify patients at high risk for having or developing AFib. AHA and its team of expert advisors are designing the tool with the intent of practical clinical implementation and scalability. Success of this tool has the potential to save millions of lives by reducing the risk of stroke in AFib patients who don’t even know they have AFib.

More News

  • Cardiac Rehabilitation Enabled With Health Technology: Innovative Models of Care Delivery and Policy to Enhance Health Equity

    Cardiac rehabilitation (CR) is a well‐established program for secondary prevention of cardiovascular…

  • Century of progress sets stage for future scientific advances in cardiovascular health

    Dramatic advances in the understanding and treatment of cardiovascular diseases have saved millions of…

  • Cardiovascular care centered on the patient is key and helps improve equity and outcomes

    Patient-centered care establishes a respectful partnership among the health care team, the…

  • Upcoming Webinar: Heart Talks: Navigating Vascular Aging for Heart Health 5/23!

    The CHTI is please to convene this group of experts on an…

Sign up for our mailing list